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Objective: Myricetin, a common dietary flavonoid is widely distributed in fruits and vegetables, and is used as a
health food supplement based on its immune function, anti-oxidation, anti-tumor, and anti-inflammatory properties.
The aim of this study was to investigate the effects of myricetin on combination with radiotherapy enhance
radiosensitivity of lung cancer A549 and H1299 cells.
Methods: A549 cells and H1299 cells were exposed to X-ray with or without myricetin treatment. Colony formation
assays, CCK-8 assay, flow cytometry and Caspase-3 level detection were used to evaluate the radiosensitization
activity of myricetin on cell proliferation and apoptosis in vitro. Nude mouse tumor xenograft model was built
to assessed radiosensitization effect of myricetin in vivo.
Results: Compared with the exposed group without myricetin treatment, the groups treated with myricetin
showed significantly suppressed cell surviving fraction and proliferation, increased the cell apoptosis and increased
Caspase-3 protein expression after X-ray exposure in vitro. And in vivo assay, growth speed of tumor xenografts was
significantly decreased in irradiated mice treated with myricetin.
Conclusions: The study demonstrated both in vitro and in vivo evidence that combination of myricetin with
radiotherapy can enhance tumor radiosensitivity of pulmonary carcinoma A549 and H1299 cells, and myricetin
could be a potential radiosensitizer for lung cancer therapy.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5791518001210633
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The morbidity and mortality of lung cancer take the first
place among malignant tumors in the world [1]. Surgery,
chemotherapy and radiation are the most three major
therapeutic options for treatment of lung cancer. In par-
ticular, more than 50% of newly diagnosed lung can-
cer patients worldwide receive radiotherapy (alone or in
combination with chemotherapy or surgery) at some point
during their treatment [2]. However, the curative potential* Correspondence: zhaogq@zzu.edu.cn; bright3072@126.com
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unless otherwise stated.of radiotherapy is often limited by intrinsic radioresistance
of cancer cells and systemic dose-limiting normal tissue
toxicity [3-5]. Therefore, there is increasing interest in
enhancing the radiosensitivity of lung cancer cells for
development of effective therapies and improve patient sur-
vival with the added benefit of reduced systemic toxicity.
Recently, much radiosensitization approaches aim to
target DNA damage responses (DDR) because the overall
function of DDR is to promote cellular survival [6-8]. And
some drugs had been reported to used as radiosensitizers
targeting DDR [9-11]. However their activities in vivo had
not been fully characterized. Though promising, one of
the major concerns of these radiosensitizers was that they
might increase normal tissue damage after radiotherapy if
used systematically. Therefore, It was essential to findLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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response threshold for cancer cells without enhancing the
radiosensitivity of normal cells [12,13].
Currently, there is growing interest in the therapeutic
applications of bioflavonoids for the treatment and pre-
vention of diseases in humans. Myricetin (3, 3’,4’, 5, 5’, 7-
hexahydroxyflavone) is a naturally occurring flavonoid
that is commonly found in tea, berries, fruits, vegetables,
and medicinal herbs et al. [14,15]. Previous studies have
shown that myricetin has antioxidant, anti-inflammatory
and potent anticancer effects [15-18]. In addition, some
studies have also shown that myricetin and quercetin (the
congener of myricetin) can reduce UV radiation-induced
skin damage and increase white blood cells in X-ray irradi-
ated mice and human peripheral blood lymphocytes after
radiotherapy [18-21]. Recently, there was a study show
that combination of quercetin with radiotherapy could en-
hance tumor radiosensitivity [22]. It was interesting to in-
vestigate whether myricetin has the function in enhancing
the radiosensitivity of cancer cells.
Non-small cell lung cancer (NSCLC) is the most pre-
dominant type of lung cancer, and about 70-80% of lung
cancer fall under the classification of NSCLC with adeno-
carcinoma as the most common subtype [23]. In this study,
we engaged NSCLC cell A549 and H1299 to observe the
effects of myricetin on combination with radiotherapy en-
hances tumor radiosensitivity in vitro and in vivo, in order
to provided a novel insight into myricetin as a potential
agent for lung cancer radiosensitizers.
Materials and methods
Cell lines and cell culture
The human lung cancer cell line A549 and H1299
were purchased from Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences. The cells were
routinely cultured in DMEM (Gibco, USA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL
penicillin and 100 μg/mL streptomycin in a humidified cell
incubator with an atmosphere of 5% CO2 at 37°C.
Experimental treatment
Experimental irradiation (IR) was performed at a dose
rate of 2.0 Gy/min in an X-ray linear accelerator (Elekta
Precise, Stockholm, Sweden) at room temperature. Myri-
cetin (>95% purity) was purchased from Sigma-Aldrich.
Treatment was given for 24 hours prior to ionizing radio-
therapy or sham radiotherapy. In vitro cell assay, myricetin
was added into the culture (final concentration 25 μM) at
1 h before irradiation.
Colony-forming survival assay
The overall survival of the cells treated with myricetin
or irradiation alone or in combination, was assessed by
the rate of colony formation. The A549 and H1299 cellswere irradiated, and the dose rate was 2.0 Gy/min. Cells
were plated into 6-well plates and exposed to doses of 0,
2, 4, 6 and 8 Gy radiation, while myricetin (final concen-
tration 25 μM) was added into the culture at 1 h before
IR and maintained for 24 h. 24 hours after radiation, all
cells were then washed, trypsinized, counted, and plated
into 10 cm dishes containing DMEM supplemented with
10% FBS until colony formation was visible, which usu-
ally occurred in approximately 2 weeks. The colonies
formed were stained with crystal violet, and the colonies
with >50 cells scored as surviving colonies. The plating
efficiency was calculated by dividing the average number
of colonies per dish by the amount of cells plated. Sur-
vival fractions were calculated by normalization to the
plating efficiency of appropriate control groups.
In vitro cell proliferation assay
A549 and H1299 cell lines in logarithmic phase growth
were seeded into 96-well plates at a density of 1 × 104
cells/well with three replicate wells of each four groups
(control group, radiotherapy (dose rate of 2 Gy) alone
group, myricetin (25 μM) group and combination group).
24, 48 and 72 hours after irradiation, OD was measured
by WST (water-soluble tetrazolium salt) assay using mi-
croplate computer software (Bio-Rad Laboratories, USA)
according to the protocol of Cell Counting Kit-8 (CCK8)
assay kit (Dojindo, Japan). 450 nm absorbance (A450)
was read on a microplate reader (168–1000 Model 680,
Bio-Rad, Hercules, USA). The curves of cell proliferation
were plotted. The experiments were performed in triplicate.
Cell apoptosis assay
A549 and H1299 cell lines in logarithmic phase growth
were seeded in 6-well plate with 2.0 × 105 cells in each
well. Four groups (control group, radiotherapy alone
group, myricetin group, and combination group) cells
were harvested and counted at 24 hours after irradiation.
The tests were performed using the annexin V-FITC/PI
apoptosis detection kit. The cell pellets were resuspended
in 195 μL of binding buffer and stained with 5 μL each of
annexin V-FITC and PI staining solution for 10 minutes
at room temperature in the dark. Flow cytometry was per-
formed with the FACScan system using CellQuest soft-
ware. Cell apoptosis rate was calculated as: (the number of
cell apoptosis in each group/the total number of cells in
each group) × 100%.
Western blot analysis
Cell harvest was same as the method of cell apoptosis
assay. Total protein was extracted from each group cells
using RIPA buffer containing PMSF. A BCA protein assay
kit (Beyotime, Haimen, China) was used to determine
total protein concentration. Proteins were electrophoresed
by SDS-PAGE and transferred onto PVDF membranes.
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at 4°C with diluted primary antibody (rabbit anti-caspase
3 antibody, 1:1000, Invitrogen) and followed by incubation
with an HRP-conjugated secondary antibody (Santa Cruz
Biotechnology). An antibody against beta-actin(Santa Cruz
Biotechnology) served as an endogenous reference. Pro-
tein intensity were scanned on Typhoon PhosphorImager
(GE Healthcare) for fluorescent signal. Experiments were
performed in triplicate.
Human tumor xenograft model in nude mouse
Immunodeficient female BALB/C nude mice, 5-6 weeks
old, were from the Experimental Animal Center of Henan
province, China. The nice were subcutaneously injected in
the dorsal scapular region with A549 cells. In addtion, a
sufficient number of mice were implanted in order that
tumors in a weight range as narrow as possible were se-
lected for the trial on the day of treatment initiation (Days
15 after tumor cells implantation). The tumors were
allowed to reach about 150 mm3 in size before the start of
treatment. Mice in the different groups were treated intra-
peritoneally with myricetin alone (20 mg/kg, once daily
for 12 days) or myricetin (1 h before radiation) plus irradi-
ation at 2 Gy fractions to a total dose of 20 Gy. The tumor
volume were measured with a caliper every 5 days, and
tumor volume was calculated using the formula: volume =
π(length × width2)/6. This study was carried out in strict
accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of Zhengzhou
University. The protocol was approved by the Committee
on the Ethics of Animal Experiments of Zhengzhou
University. All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to
minimize suffering.
Statistical analysis
SPSS 13.0 was used for statistical analysis. One-way
analysis of variance (ANOVA) was used to analyze the
significance between groups. Multiple comparisons were
made using the Least Significant Difference test when the
probability for ANOVA was statistically significant. All
data represent mean ± SD. Statistical significance was set
at P < 0.05.
Results
Myricetin increased radiosensitization of tumor cells
in vitro
To determine the effects of myricetin on cells radio-
sensitivity, a clonogenic survival analysis was per-
formed. It was found that treatment of the A549 cells
with myricetin alone led to a minimal effect on clono-
genic survival (Figure 1A and B). However, when com-
bined with radiation, the surviving fraction decreased
significantly (Figure 1C and D).Myricetin enhances radiosensitivity on inhibiting the
A549 and H1299 cells’ proliferation
CCK-8 assay was used to measure the effect of radiosen-
sitization activity of myricetin on the growth and viabil-
ity of A549 and H1299 cells in vitro. Compared to the
control, both the proliferation of A549 cells (Figure 2A)
and H1299 cells (Figure 2B) were inhibited significantly in
myricetin group, radiotherapy group and radiotherapy +
myricetin combination group. It was aslo found that
myricetin-only had but only limited inhibitory effect
on tumor cells proliferation. However, a significant de-
crease in tumor proliferation occurred for irradiated cells
treated with myricetin. The result demonstrated that myr-
icetin enhanced the radiosensitivity of cancer cells and has
the function as a tumor radiosensitizer in lung cancer cells
in vitro.
Radiosensitizing effect of myricetin on tumor cells
apoptosis
To investigate the apoptosis effect of myricetin-induced
radiosensitization, we firstly used flow cytometry (FCM)
to measure the effect of myricetin and irradiation on
apoptosis in A549 and H1299 cells. As shown in Figure 3A,
Compared to the control, both the apoptosis rate of A549
cells and H1299 cells were increased in myricetin-alone
group and radiotherapy-alone group (P < 0.05). And fur-
thermore, the apoptosis rate was significantly enhanced
in radiotherapy + myricetin combination group. Mean-
while, compared with the radiotherapy alone group, the
the apoptosis effect was obviously enhanced in radio-
therapy +myricetin combination group (P < 0.05).
To further test the radiosensitizing effect of myricetin
on tumor cells apoptosis, we aslo engaged the western
blot to detect the expression of Caspase-3 protein. As
shown in Figure 3B and C, compare to the control, the ex-
pression level of Caspase-3 were higher in myricetin-alone
group and radiotherapy-alone group than in control group
(P < 0.05). And the expression level of Caspase-3 were in-
creased significantly in radiotherapy +myricetin combi-
nation group than in other three groups (P < 0.05).
The radiosensitizing effect of myricetin in vivo
Because myricetin has the radiosensitization activity on
cell survival, prolifation and apoptosis in vitro, we per-
formed a proof-of-principle experiment using a lung cancer
A549 cell xenograft mice model to determine radiosensitiz-
ing effect of myricetin in vivo. The dose of myricetin used
was 20 mg/kg (once daily for 12 days, for a total dose of
240 mg/kg). Radiation therapy (2 Gy/fraction, 5 times/
week for a total dose of 20 Gy) was given locally to the
tumor xenografts and scheduled to fit the myicetin admi-
nistration. We found that myicetin-alone group had less
inhibitory effect on tumor growth, compared with tumors
treated with radiotherapy-alone (Figure 4). However, a
Figure 1 Myricetin radiosensitizes cancer cells in vitro. (A) and (B) Myricetin alone on clonogenic survival in A549 and H1299 cells lines.
Cells were treated with indicated doses of myricetin for 24 h and colony formation assays were conducted. Compared to the control, there was
little effect on clonogenic survival treated with different doses myricetin (P < 0.05). (C) Radiosensitivity was measured by colony formation assay
in the human lung cancer cell line A549 treated with control or 25 μM of myricetin (1 h before IR and maintained for 24 h), Compared to the
control, clonogenic survival of A549 cells treated with myricetin were decreased significantly under different irradiation doses. (D) Radiosensitivity
of the human lung cancer cell line H1299. Shown are averages of triplicate samples. Standard errors are shown by error bars.
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radiated mice treated with myricetin. These results de-
monstrated that myricetin could increase lung tumor cell
killed by radiation in vivo, and further indicated that myri-
cetin can function as a powerful radiosensitizer for lung
cancer.
Discussion
Radiotherapy plays an important part in the management
of lung cancer [24]. However, partial lung cancer cell’s re-
sistance to radiotherapy affects therapeutic effects, and 5-
year survival rate of radiotherapy alone is only 5%–10%,
local recurrence occurs in 80% of patients, and metastasis
occurs in 60% of patients [25]. Therefore, it is necessary toFigure 2 Myricetin enhances radiosensitivity on inhibiting the tumor
in the human lung cancer cell line A549 treated with 25 μM of myricetin a
for 24 h), Compared to the radiotherapy alone group, the proliferation of A
myricetin group. (B) Radiosensitivity of the human lung cancer cell line H1find a effective radiosensitizer to enhance tumor radiosen-
sitivity, while with less negtive function to normal tissues.
Myricetin, a nontoxic dietary flavonoid, could be easily
found in many natural foods and medicinal herbs [26,27].
Reports indicate that myricetin does not cause tumor
formation in mice and attenuates the number of diol-
epoxide-induced pulmonary tumors per mouse [28]. It
inhibits polycyclic aromatic hydrocarbon metabolism
and subsequent polycyclic aromatic hydrocarbon–DNA
adduct formation in lung [29]. And many studies have
shown that myricetin has antioxidant, anti-inflammatory
and potent anticancer effects [15-18]. Therefore it was
reasonable to hypothesize that myricetin might function
as a radiosensitizer.cell proliferation. (A) Radiosensitivity was measured by CCK-8 assay
lone or myricetin plus radiotherapy (1 h before IR and maintained
549 cells were slower down significantly in radiotherapy combine with
299, which results was same as the A549.
Figure 3 Radiosensitizing effect of myricetin on tumor cells apoptosis. (A) Myricetin increase the radiosensitivity of apoptosis rate in A549 and
H1299 cells. The cells were stained by annexin V-FITC/PI, and cell apoptosis was analyzed by FCM. The data showed that apoptotic cells was statistically
significant increased (*P < 0.05) in radiotherapy +myricetin combination group, compared to other three groups. (B) Western blot for Caspase-3
expression in control (c), myricetin-alone (M), radiotherapy-alone (R) and radiotherapy +myricetin combination (M+ R) group. (C) Myricetin increase
the Caspase-3 expression in occurred for radiotherapy in A549 and H1299 cells. The data aslo showed higher expression of Caspase-3 (*P < 0.05) in
radiotherapy +myricetin combination group, compared to other three groups. Data are presented as the mean of triplicate experiments.
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formation assays and prolifetation assay in lung cell lines
(A549 and H1299), It was found that treatment of the
cells with radiotherapy combined with myricetin could
significantly decrease the surviving fraction and prolife-
tation of cancer cells. And in this study, we aslo engaged
lung tumor bearing nude mice model to observe the
radiosensitizing effect of myricetin in vivo. The result
showed the tumor growth speed was significantly slower
down in occurred for irradiated mice treated with myri-
cetin. These data above demonstrate that myricetin hasa radiosensitization potential in vitro and in vivo, and
further indicated that myricetin can function as a power-
ful radiosensitizer for lung cancer.
Apoptosis is an important effect in the use of radiation
to kill tumor cells, and it is now widely recognized that
radiation-induced apoptosis may be used to measure the
sensitivity of cells to radiation, with an increased rate of
apoptosis meaning that the cells have a higher sensitivity
to radiation [30-35]. In order to investigate the apop-
tosis effect of myricetin-induced radiosensitization, the
apoptosis rate of A549 and H1299 cells were measured
Figure 4 A549 cell xenograft tumor for detecting myricetin
sensitizing tumors to irradiation in vivo. A549 cells were
implanted subcutaneously in immunodeficient female BALB/C nude
mice. Mice treated with myricetin alone (20 mg/kg, once daily for
14 days) or myricetin plus radiotherapy (myricetin was given 1 h
before IR) at 2-Gy fractions for a total dose of 20 Gy. Shown are
medium tumor volume of each group as function of time after
implantation. The data curve showed that radiotherapy combine
with myricetin could inhibit the tumor growth significantly,
compared with other three groups.
Zhang et al. Diagnostic Pathology 2014, 9:68 Page 6 of 7
http://www.diagnosticpathology.org/content/9/1/68through FCM. The results showed that myricetin en-
hanced the radiosensitivity of apoptosis rate in lung cancer
cells. And to further test the radiosensitizing effect of
myricetin on tumor cells apoptosis, we detected the ex-
pression level of Caspase-3, which was plays a very im-
portant role during cells apoptosis. The data showed that
myricetin could increase the expression of Caspase-3 in
occurred for radiotherapy, which aslo indicated that myri-
cetin could enhanced the radiosensitivity of apoptosis.
In conclusion, the results of the current study demon-
strate the effect of myricetin on combination with radio-
therapy enhances lung tumor radiosensitivity in vitro and
in vivo, it could provied a novel insight into myricetin as a
safe and potential agent for lung cancer radiosensitizers to
enhance the effectiveness of radiotherapy.
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